Premium
Cardiovascular effects of sitagliptin – An anti‐diabetes medicine
Author(s) -
Zhou Yi,
Guo Zhiying,
Yan Wenjing,
Wang Wen
Publication year - 2018
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.12953
Subject(s) - sitagliptin , alogliptin , linagliptin , medicine , saxagliptin , dipeptidyl peptidase 4 , diabetes mellitus , pharmacology , vildagliptin , metformin , oxidative stress , type 2 diabetes , incretin , endocrinology
Summary Dipeptidyl‐peptidase‐4 ( DPP ‐4) inhibitors, as the most recent available anti‐diabetic agents, were generally used in clinical treatment of type 2 diabetes (T2 DM ). In addition to anti‐diabetic effects, the five most widely used DPP ‐4 inhibitors (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin) also exert cardiovascular protective effects. In recent years, increasing studies suggest that sitagliptin shows pleiotropic impacts towards the cardiovascular system either with or without diabetes. In this review, we summarized the recent reports to provide an update discussion about cardiovascular protective effects of sitagliptin and the corresponding mechanisms. Sitagliptin has positive effects towards ischaemic cardiovascular diseases, atherosclerosis and hypertension. These effects are mainly conducted through DPP ‐4 inhibitions. In addition, sitagliptin exerts anti‐inflammation, anti‐oxidative stress, anti‐apoptosis, mediation on lipid accumulation and so on, which also contribute to its cardiovascular effects.